HWAM
TSHA icon

Hennion & Walsh Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Buy
519,120
+127,644
+33% +$755K 0.1% 253
2026
Q1 		$1.75M Buy
391,476
+83,019
+27% +$386K 0.06% 381
2025
Q4 		$1.7M Buy
+308,457
New +$1.5M 0.06% 394

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hennion & Walsh Asset Management's TSHA Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Taysha Gene Therapies (TSHA) stake by 33% in Q2 2026, buying an estimated $755K and bringing the position to 519,120 shares worth $3.54M. The position accounts for 0.1% of the portfolio, ranked #253.

Hennion & Walsh Asset Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Hennion & Walsh Asset Management held 519,120 shares of Taysha Gene Therapies worth $3.54M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 127,644 Taysha Gene Therapies shares in Q2 2026, an estimated $755K.
  • Taysha Gene Therapies made up 0.1% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #253 holding.
  • Hennion & Walsh Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.